Cocrystal Pharma (NASDAQ:COCP) vs. Phibro Animal Health (NASDAQ:PAHC) Head to Head Analysis

Phibro Animal Health (NASDAQ:PAHC) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Volatility and Risk

Phibro Animal Health has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.

Profitability

This table compares Phibro Animal Health and Cocrystal Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Cocrystal Pharma	N/A	-207.47%	-123.33%

Insider and Institutional Ownership

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 48.5% of Phibro Animal Health shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Phibro Animal Health and Cocrystal Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52 billion	1.04	$99.72 million	$2.44	15.91
Cocrystal Pharma	$330,000.00	59.54	-$8.83 million	($0.76)	-1.34

Phibro Animal Health has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Phibro Animal Health and Cocrystal Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0	2	1	1	2.75
Cocrystal Pharma	1	0	1	0	2.00

Phibro Animal Health currently has a consensus target price of $47.67, suggesting a potential upside of 22.79%. Given Phibro Animal Health’s stronger consensus rating and higher probable upside, analysts plainly believe Phibro Animal Health is more favorable than Cocrystal Pharma.

Summary

Phibro Animal Health beats Cocrystal Pharma on 12 of the 14 factors compared between the two stocks.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

About Cocrystal Pharma

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.